{"name":"Keymed Biosciences Co.Ltd","slug":"keymed-biosciences-co-ltd","ticker":"","exchange":"","domain":"","description":"Keymed Biosciences Co., Ltd is a biotechnology company focused on the research and development of innovative therapies. The company has a pipeline of 37 drugs, with several in phase 1 and phase 2 clinical trials, primarily targeting oncology and immunology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CM310","genericName":"CM310","slug":"cm310","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CM326","genericName":"CM326","slug":"cm326","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"CM338 Injection","genericName":"CM338 Injection","slug":"cm338-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"CM313 injection","genericName":"CM313 injection","slug":"cm313-injection","indication":"Other","status":"phase_2"},{"name":"CM512","genericName":"CM512","slug":"cm512","indication":"Other","status":"phase_2"},{"name":"Stapokibatrt","genericName":"Stapokibatrt","slug":"stapokibatrt","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"CM310","genericName":"CM310","slug":"cm310","phase":"phase_3","mechanism":"CM310 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"CM326","genericName":"CM326","slug":"cm326","phase":"phase_3","mechanism":"CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"CM313 injection","genericName":"CM313 injection","slug":"cm313-injection","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CM338 Injection","genericName":"CM338 Injection","slug":"cm338-injection","phase":"phase_2","mechanism":"CM338 Injection is a monoclonal antibody targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"CM512","genericName":"CM512","slug":"cm512","phase":"phase_2","mechanism":"CM512 is an investigational therapeutic targeting a specific molecular pathway in early clinical development by Keymed Biosciences.","indications":[],"catalyst":""},{"name":"Stapokibatrt","genericName":"Stapokibatrt","slug":"stapokibatrt","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - GlobeNewswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVHI4MG5idDZaMUVwODRYVXZIcEhlbFlOaFpvQkVVaDdwNFMzYmdURWlkY3JHM01LX2dSY01HdXU3MG9wYjFtSUcyU2VGVGd6amJYc2tnQVpEd3R0dlE2aHhLMEF1ZXFYN29OVlRldzYtd25VdmtWWjE4a1RJNFZKbXpwNGU4ZGxDc0lmdmY1LWFTSkRmNi1TU05wTQ?oc=5","date":"2025-06-03","type":"pipeline","source":"BioWorld News","summary":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld News","headline":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOSkFOUFNlZC1BR0tYYkdSdGdWREZHMGZPR1d3U2J5czVzMFZhX0N4SFhkcWw5V3pfS3BvSzNsZGdFRElyUGkxd1RyREd1SkJ0X2FVSy1tZW94OHdWclVBTlNkMy1TSWlQNE9IUGRSQnJaazZ6U1FrYUQ1bFYzNUFLdkZ5djdFXzZyd0RlQldLWlIxc3daNXAtMjNzbG5xWklRd1hUMkM5S29VZUxrSkRCUlY3eHN2SzB5YndTRG1aQ05CMVZ6Wlg2Z2oweE9uVWlkNVk1Q01Dd0pRcXhrb2p3ZXJ1cFJqRFJsbWllWU1rbURVOWFYU0R6bm0yVXg?oc=5","date":"2025-05-12","type":"trial","source":"PR Newswire","summary":"Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPWVJzLWIyUDhKUVpiNXJHcHFPanFOU2Fud0NLTnpHTl9kSTl6MHBBdlo1NHVrOTRwcGxhMlk0dnZjMUpDVjlrek9CdmpudkRQWHFaTlhLNTV1aXdudDNFT2VXNnZlbGpPMExmRzRtcDIzcVYxS1dkSURvVjAwejF2ODFuQm9XcXpnX0w4TWYxcFRHei12NFl3cmxIYTJONVZmb2x4eFdOVm5XTTNxVXhybEZqQXJrd0lDUl95VmVnNUZ2TDFrTTRLLUx6Zk9oNEM1WkpoOG40Y3JoMlFvblZvT3dNWEh4MnJXQjFCSmdWbkdUWmZOLWwybUcxeWE1dXNSanFr?oc=5","date":"2025-01-21","type":"deal","source":"BioPharma APAC","summary":"InnoCare Pharma, KeyMed Biosciences, and Prolium Bioscience Partner on $520M Global Licensing Deal for CD20xCD3 Bispecific Antibody - BioPharma APAC","headline":"InnoCare Pharma, KeyMed Biosciences, and Prolium Bioscience Partner on $520M Global Licensing Deal for CD20xCD3 Bispecif","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNUzY5emJTMlJWWll5Nmo5VmtBX0ZCRUFZNk9FSXRPdFhjUTRxV1VGYTZ1ZW9lajlMUUdJNGxJUTgzeldaeXZhUVdRZG9mam1CRVRudW5wQkx2bTFXUWhFMll6bm4xd3ZkUHF1aWExQjRLcF9Na1RXd29falVsWTFweWhzdzk4Sk1hUk1VaDhZakhVczhZdHRYSHVZSW83dVB5OG9VdE8td0J5VmU1UFY2UHdKMA?oc=5","date":"2025-01-21","type":"deal","source":"Fierce Biotech","summary":"InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal - Fierce Biotech","headline":"InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPUjN3Q1NDLTdBVEdnanRjT0VlWGRBS1A2TXNUXzFyR2VlaEtaYWl2UVhYcXRzSkl5VHVaakJINTVpbU5MZ3h6THRLcVlXYjktUTVjd19ONnNicmdzcEFIMTVpNXh3cjlHdW91TXMyWnlQdGJvSGtnUzFHNzhEUmZSSllyUVlnUXEyaXoxcDBqT0lOLTR1Z01yekRzVlpZUWxnczNzalk1U01BTUtYNFd6dFpJVGlYT3lTQlUtdERNcw?oc=5","date":"2025-01-21","type":"pipeline","source":"Yicai Global","summary":"China's KeyMed, InnoCare Grant Prolium Bio Global Rights to Cancer Drug for USD520 Million - Yicai Global","headline":"China's KeyMed, InnoCare Grant Prolium Bio Global Rights to Cancer Drug for USD520 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4xdk44WUtvOWdxUE55QXV4Vm1teW5DbVZHUThKTGc1TUdVRnFYSjd1TzdUaUZJa3djX0xPNGwtMmRYVTZWT0NrWV9qeTRXaWhrdURZ?oc=5","date":"2025-01-20","type":"deal","source":"FirstWord Pharma","summary":"RTW-backed Prolium latest to tap China biotech pipeline in $520M deal - FirstWord Pharma","headline":"RTW-backed Prolium latest to tap China biotech pipeline in $520M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNazhhbDlwWG1EaUN4V0RLSWhtc1hOai1zMWtxLXBIYUFWNDZORmhQekRtZEZCLTdDRWxyR3FmWWRieTdlZEpZc2ljTUtPVmk5bjJfTFJNQWh3cjdlNmllWmdFTEI0N2V2ZlBfdkdUa2pNNXY2TU5tNlYzVWxUQUtJWXdId3hJYk0zazNqc1JGN0tUSlVoVEV1U2dkRnl0Z0pza0ZFdFVlQ2NIS28yU2lkQnZIYWZ1TU10LWhTM3MtMTF0bHVHQjYwMGgyQ2pRRVhydEFYTUpFVUsyUnVkNVZpNnhtLVNTX25oNmxBTGNzajIyOHI2bWRDaVVHZEdxUQ?oc=5","date":"2025-01-20","type":"deal","source":"Business Wire","summary":"InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02 - Business Wire","headline":"InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQNzBfRnVhdzQwSHZkMTFSZEJGNHl2RmR2aDhiNE9XdGV0YXA5RTl1SlAwNEQ0YVlxaTV2WDJOQTNrRmxmaXNEVGo2eV9McHoyZFlsUDdvNmFyMUl4am5nUEstQkFfS216dlljbFhsVFpNMkFOMkplTURaR0dwM2NicUpHaXhOaDUyQXo4ZnQ0Vlc1enI0d19vdzl0b05xY1hFODg0M1pxOGhnTl9UYTcwdjA4VDFUOU5PTnp1YVZ4T3VRMGIz?oc=5","date":"2024-10-10","type":"pipeline","source":"morganlewis.com","summary":"Understanding the NewCo Model: A Trending Approach of Chinese Pharmaceutical Companies - morganlewis.com","headline":"Understanding the NewCo Model: A Trending Approach of Chinese Pharmaceutical Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNSEd2cG5fcEIyTnV4T0szSVk0M21RYjBvY1BfT3lpM3ZYWlBhNEgtMUt6aXhzX3lUeWZHelNpUTZuZmdCUGcxQXVKakRzYmJ5Ykx1andKVUlzYWhQNTVCMXBtNzlTOS1hZmxsR25IaGotV1JwcnVZc251QURlT1VZbG9Pczk5TVA4Z1EtbkxNUXhHNGVfZG1pa2Y4X3QwVEtkLVVwQWN2aTJyU0NFVV9lWF9Pc2lIbFBNTE92YVlCNzdYM3NZ?oc=5","date":"2023-02-23","type":"deal","source":"Contract Pharma","summary":"Keymed, Lepu Biopharma Enter Global License Agreement with AstraZeneca for CMG901 - Contract Pharma","headline":"Keymed, Lepu Biopharma Enter Global License Agreement with AstraZeneca for CMG901","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE53ZDY1VWtZUnF1MnNpSWJqS0xnOXJ5SjhtQXI2a2Y1blVRb3hVUS0yRk9hWDlxM1FQaVE4andPenNNQmNpb0Y4QVBraE9TbXgzVFFkOTZR?oc=5","date":"2021-07-28","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Keymed Biosciences Inc. (2162.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Keymed Biosciences Inc. (2162.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":3,"phase_2":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}